Role of Complement Activation in Severe COVID-19
补体激活在严重 COVID-19 中的作用
基本信息
- 批准号:10765317
- 负责人:
- 金额:$ 18.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAntiviral ResponseAttenuatedBloodBody Weight decreasedCOVID-19COVID-19 mortalityCOVID-19 pathogenesisChemicalsClinical ResearchComplementComplement ActivationComplement InactivatorsDataDevelopmentDietDietary SupplementationDiseaseDoseEpithelial CellsFibrosisFosteringGenesHumanInflammationInflammatory ResponseInfluenzaInjuryInnate Immune ResponseInterferonsK-18 conjugateKeratinLong COVIDLungModalityMolecularMorbidity - disease rateMusN-3 polyunsaturated fatty acidNutritionalOmega-3 Fatty AcidsPolyunsaturated Fatty AcidsProliferatingProteinsPulmonary FibrosisResearchRoleSARS-CoV-2 infectionStructureSystemTestingTherapeuticTissuesassaultcytokineimprovedinfluenza infectioninfluenzaviruslipid mediatorlung injurylung regenerationmortalitymouse modelresponsesevere COVID-19tissue repairtool
项目摘要
PROJECT ABSTRACT
We recently developed sub-lethal lethal mouse model of Covid-19 (K18-hACE2). We infected
these mice with influenza virus or sublethal SARS-CoV-2 infected K18-hACE2 mice to study
pathobiology of Covid-mild 19 disease and to identify treatment modalities for long Covid. These
studies revealed that both influenza and sub-lethal dose of SARS-CoV-2 causes transients weight
loss and damage lung epithelial cells as expected. However, influenza induced inflammation was
resolved by proliferation of basal lung epithelial cells organized into pod structure and lung
regeneration while sub-lethal SARS-CoV-2 induced inflammation resulted in lung fibrosis. At the
molecular level influenza infection induced expression of Keratin genes (Krt5, 15, 16) at
dramatically higher levels compared to sub-lethal dose of SARS-CoV-2, consistent with tissue
repair in lungs of influenza but fibrosis in the lungs of sub-lethal SARS-CoV-2 infected mice.
Importantly, influenza induced much stronger interferon response while SARS-CoV-2 induced
much stronger cytokine response, complement response, and fibrosis. These data indicate that
a more robust innate immune response, attenuated cytokine and complement response, and
activation of pro-resolving molecules may help reduce the mortality and morbidity of SARS-CoV-
2. Omega 3 polyunsaturated fatty acids (n-3 PUFAs) fulfil these criteria because they activate
direct anti-viral response proteins and are the precursors of the pro-resolving lipid mediators that
favor tissue repair. Indeed, n-3 PUFAs reduce lung fibrosis induced by various chemical and
environmental assaults.
In this supplemental proposal we will feed sub-lethal SARS-CoV-2 infected mice with n-3
PUFA or n-6 PUFA (control) supplemented diets to test the hypothesis that n-3 PUFAs will
improve innate immune response to SARS-CoV-2 infection by moderating the initial injury as
determined by weight loss and initial lung injury. We hypothesis further that by increasing tissue
and blood concentration of pro-resolving lipid mediators, n-3 PUFAs will promote tissue repair
over fibrosis in mice infected with sub-lethal dose of SARS-CoV-2. If these studies are successful
they will open a path for human clinical studies aimed at using n-3 PUFAs as nutritional
substances to reduce morbidity of long Covid, either alone or in combination with other agents
such as complement inhibitors.
项目摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xuebin Qin其他文献
Xuebin Qin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xuebin Qin', 18)}}的其他基金
Role of Complement Activation in Severe COVID-19
补体激活在严重 COVID-19 中的作用
- 批准号:
10512248 - 财政年份:2022
- 资助金额:
$ 18.66万 - 项目类别:
Role of Complement Activation in Severe COVID-19
补体激活在严重 COVID-19 中的作用
- 批准号:
10687821 - 财政年份:2022
- 资助金额:
$ 18.66万 - 项目类别:
Generation and Characterization of a Novel Cell Subpopulation Ablation Model
新型细胞亚群消融模型的生成和表征
- 批准号:
9932578 - 财政年份:2019
- 资助金额:
$ 18.66万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
8791256 - 财政年份:2013
- 资助金额:
$ 18.66万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
8725332 - 财政年份:2013
- 资助金额:
$ 18.66万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
9001317 - 财政年份:2013
- 资助金额:
$ 18.66万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
8438708 - 财政年份:2013
- 资助金额:
$ 18.66万 - 项目类别:
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
开发用于治疗 B 细胞恶性肿瘤的治疗性 CD59 抑制剂
- 批准号:
8607165 - 财政年份:2013
- 资助金额:
$ 18.66万 - 项目类别:
相似海外基金
Regulation of RIG-I mediated antiviral response upon influenza A virus infection
RIG-I介导的甲型流感病毒感染抗病毒反应的调节
- 批准号:
494286 - 财政年份:2023
- 资助金额:
$ 18.66万 - 项目类别:
Operating Grants
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy
激活 DNA-PK 依赖性抗病毒反应作为一种新型癌症免疫疗法
- 批准号:
10364056 - 财政年份:2022
- 资助金额:
$ 18.66万 - 项目类别:
ADAR1-mediated antiviral response in Zika virus (ZIKV) infection
ADAR1 介导的寨卡病毒 (ZIKV) 感染抗病毒反应
- 批准号:
10621913 - 财政年份:2022
- 资助金额:
$ 18.66万 - 项目类别:
Activation of the DNA-PK-dependent antiviral response as a novel cancer immunotherapy
激活 DNA-PK 依赖性抗病毒反应作为一种新型癌症免疫疗法
- 批准号:
10553146 - 财政年份:2022
- 资助金额:
$ 18.66万 - 项目类别:
ADAR1-mediated antiviral response in Zika virus (ZIKV) infection
ADAR1 介导的寨卡病毒 (ZIKV) 感染抗病毒反应
- 批准号:
10373627 - 财政年份:2022
- 资助金额:
$ 18.66万 - 项目类别:
Mechanisms of IgE-mediated regulation of monocyte antiviral response pathways
IgE介导的单核细胞抗病毒反应途径的调节机制
- 批准号:
10640247 - 财政年份:2021
- 资助金额:
$ 18.66万 - 项目类别:
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infection
AMPK 和 Hippo 信号传导之间的相互作用调节眼部对寨卡病毒感染的抗病毒反应
- 批准号:
10322026 - 财政年份:2021
- 资助金额:
$ 18.66万 - 项目类别:
Mechanisms of IgE-mediated regulation of monocyte antiviral response pathways
IgE 介导的单核细胞抗病毒反应途径调节机制
- 批准号:
10438876 - 财政年份:2021
- 资助金额:
$ 18.66万 - 项目类别:
Antiviral response coupled with transposon derepression in Alzheimer's disease and aging
抗病毒反应与转座子去抑制在阿尔茨海默病和衰老中的作用
- 批准号:
10629440 - 财政年份:2021
- 资助金额:
$ 18.66万 - 项目类别:
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
- 批准号:
10373575 - 财政年份:2021
- 资助金额:
$ 18.66万 - 项目类别:














{{item.name}}会员




